Show simple item record

dc.contributor.authorAndrew, Kashini
dc.contributor.authorDhariwal, Sukhjit K
dc.contributor.authorSzczecinska, Weronika
dc.date.accessioned2023-09-06T11:44:19Z
dc.date.available2023-09-06T11:44:19Z
dc.date.issued2023-08
dc.identifier.citationClin Exp Dermatol . 2023 Aug 25;48(9):1055-1056en_US
dc.identifier.eissn1365-2230
dc.identifier.doi10.1093/ced/llad173
dc.identifier.pmid37146158
dc.identifier.urihttp://hdl.handle.net/20.500.14200/2117
dc.description.abstractNo abstract availableen_US
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.subjectDermatologyen_US
dc.titleSarilumab (interleukin-6 receptor monoclonal antibody) for the treatment of pemphigus vulgaris.en_US
dc.typeArticle
dc.source.journaltitleClinical and Experimental Dermatology
dc.source.volume48
dc.source.issue9
dc.source.beginpage1055
dc.source.endpage1056
dc.source.countryEngland
rioxxterms.versionNAen_US
dc.contributor.trustauthorAndrew, Kashini
dc.contributor.trustauthorSzczecinska, Weronika
dc.contributor.departmentMedicineen_US
dc.contributor.roleMedical and Dentalen_US
oa.grant.openaccessnaen_US


This item appears in the following Collection(s)

Show simple item record